GlassScriptPhysician profile
Walter J Cukrowski
NPI 1720078587
$3,045.58
in general payments reported to CMS, 2019-2025
25 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $536 · 2020: $203 · 2021: $740 · 2022: $291 · 2023: $760 · 2024: $407 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,276.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $681.86 | 2019-2024 | Istent Trabecular Micro-Bypass System Model Is3, Istent Inject Trabecular Micro-Bypass System Model G2-M-Is, Photrexa Cross-Linking Kit |
| Carl Zeiss Meditec USA, INC. | $276.00 | 2023 | Veracity Surgical, Iolmaster 700, Lumera 700 |
| Alcon Vision LLC | $262.76 | 2019-2025 | Tryptyr |
| Kala Pharmaceuticals, INC. | $226.60 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $214.69 | 2019-2021 | |
| Abbvie INC. | $156.97 | 2022-2024 | Lumigan |
| Eyevance Pharmaceuticals LLC | $149.24 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $123.48 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $114.50 | 2022-2024 | Vyzulta, Lotemax Sm, Prolensa |
| Allergan, INC. | $107.23 | 2020-2022 | |
| Oyster Point Pharma, INC. | $102.09 | 2023-2024 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $99.38 | 2019-2023 | |
| Thea Pharma INC. | $80.44 | 2023-2025 | Iyuzeh |
| Johnson & Johnson Surgical Vision, INC. | $79.25 | 2019 | |
| Shire North American Group INC | $78.28 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $60.00 | 2024 | |
| Amgen INC. | $38.98 | 2024 | Tepezza |
| Rxsight INC | $31.37 | 2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Quidel Corporation | $29.32 | 2023 | |
| Sun Pharmaceutical Industries INC. | $29.18 | 2019-2024 | |
| Harrow Eye, LLC | $25.73 | 2025 | Iheezo |
| Mallinckrodt Hospital Products INC. | $23.67 | 2021 | |
| New World Medical,INC. | $21.20 | 2025 | Ahmed Glaucoma Valve, Kahook Dual Blade, Streamline |
| Rayner Intraocular Lenses Limited | $17.81 | 2022 | |
| Sight Sciences, INC. | $15.55 | 2023 | Omni Surgical System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Cukrowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.